MCID: FBR009
MIFTS: 37

Fibrous Dysplasia malady

Categories: Rare diseases, Bone diseases

Aliases & Classifications for Fibrous Dysplasia

About this section

Aliases & Descriptions for Fibrous Dysplasia:

Name: Fibrous Dysplasia 10 45 47 12 65
 
Fibrous Dysplasia of Bone 45

Classifications:



External Ids:

Disease Ontology10 DOID:0080031
ICD1027 M85.0
UMLS65 C0259779

Summaries for Fibrous Dysplasia

About this section
NIH Rare Diseases:45 Fibrous dysplasia is a skeletal disorder that is characterized by the replacement of normal bone with fibrous bone tissue. it may involve one bone (monostotic) or multiple bones (polyostotic). fibrous dysplasia can affect any bone in the body. the most common sites are the bones in the skull and face, the long bones in the arms and legs, the pelvis, and the ribs. though many individuals with this condition do not have any symptoms, others may have bone pain, abnormally shaped bones, or an increased risk of fractures (broken bones). this condition can occur alone or as part of a genetic disorder, such as mccune-albright syndrome. while there is no cure for fibrous dysplasia, the symptoms can be treated. medications known as bisphosphonates can reduce pain and surgery may be indicated for fractures or to correct misshapen bones.  last updated: 4/4/2016

MalaCards based summary: Fibrous Dysplasia, also known as fibrous dysplasia of bone, is related to paroxysmal nocturnal hemoglobinuria and parenchymatous neurosyphilis. An important gene associated with Fibrous Dysplasia is GNAS (GNAS Complex Locus), and among its related pathways are Osteoblast Signaling and Interleukin-11 Signaling Pathway. Affiliated tissues include bone, breast and brain.

Disease Ontology:10 A bone remodeling disease that results in the destruction of normal bone and replacing it with fibrous bone tissue.

Related Diseases for Fibrous Dysplasia

About this section

Diseases related to Fibrous Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 568)
idRelated DiseaseScoreTop Affiliating Genes
1paroxysmal nocturnal hemoglobinuria30.1CALCA, SST
2parenchymatous neurosyphilis30.1CALCA, GNAS
3dementia30.0BGLAP, CALCA, FGF23
4pituitary adenoma29.9GH1, PRL
5ovarian cyst29.7CALCA, PRL
6obesity29.3BGLAP, GH1, GNAS, PRL, SST
7monostotic fibrous dysplasia12.6
8mccune-albright syndrome, somatic, mosaic12.4
9panostotic fibrous dysplasia12.4
10fibrous dysplasia/mccune-albright syndrome12.3
11mazabraud syndrome11.8
12cherubism11.6
13properdin deficiency, x-linked11.3
14osteofibrous dysplasia11.3
15free sialic acid storage disorders10.5GH1, GNAS
16prostatitis10.4
17chief cell adenoma10.4BGLAP, SPARC
18leukemia10.4
19epileptic encephalopathy, early infantile, 2610.4BGLAP, GNAS
20aromatase excess syndrome10.4BGLAP, GH1
21precocious puberty, gonadotropin-dependent10.4GH1, GNAS
22endotheliitis10.4
23prion disease10.4BGLAP, SPARC
24neuronitis10.4
25fibrogenesis imperfecta ossium10.3ALPP, BGLAP
26rectosigmoid junction neoplasm10.3BGLAP, SPARC
27adrenal neuroblastoma10.3GNAS, SST
28prostate cancer10.3
29thyroiditis10.3
30neuropathy10.3
31paracoccidioidomycosis10.3ALPP, SPARC
32in situ pulmonary adenocarcinoma10.3GNAS, SST
33bone osteosarcoma10.3GNAS, SPARC
34retinitis10.3
35kidney disease10.3
36parathyroid adenoma10.3BGLAP, CALCA
37hypoaldosteronism10.3CALCA, GH1
38pachyonychia congenita10.3CALCA, FGF23
39paresthesia10.3CALCA, FGF23
40hepatitis10.3
41chest wall lymphoma10.3CALCA, SPARC
42ulceration of vulva10.3BGLAP, CALCA
43bone structure disease10.2ALPP, BGLAP
44articulation disorder10.2BGLAP, GNAS
45acrodermatitis chronica atrophicans10.2BGLAP, CALCA
46mononeuritis10.2CDC73, GNAS
47osteogenesis imperfecta levin type10.2BGLAP, GNAS, SPARC
48achondrogenesis10.2ALPP, CALCA
49arthritis10.2
50cervicitis10.2

Graphical network of the top 20 diseases related to Fibrous Dysplasia:



Diseases related to fibrous dysplasia

Symptoms for Fibrous Dysplasia

About this section

Drugs & Therapeutics for Fibrous Dysplasia

About this section

Drugs for Fibrous Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Etidronic acidapprovedPhase 2, Phase 3427414-83-73305
Synonyms:
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonic acid
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1,1,1-Ethanetriol diphosphonate
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonic acid
Acide etidronique
Acide etidronique [INN-French]
Acido etidronico
Acido etidronico [INN-Spanish]
Acidum etidronicum
Acidum etidronicum [INN-Latin]
BPBio1_000997
BRN 1789291
BSPBio_000905
Bio-0708
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
 
CID3305
Cintichem Technetium 99m Hedspa
D02373
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Diphosphonate (base)
EHDP
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronate Disodium
Etidronate disodium
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MPI Stannous Diphosphonate
MolPort-001-786-542
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonic acid
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
SMR000038750
SPBio_002826
STK721995
Turpinal SL
UNII-M2F465ROXU
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
2HormonesPhase 3, Phase 2, Phase 111748
3Bone Density Conservation AgentsPhase 2, Phase 32600
4DiphosphonatesPhase 2, Phase 3381
5Risedronate SodiumPhase 2, Phase 398115436-72-1
6Calcium, DietaryPhase 2, Phase 34678
7calcium channel blockersPhase 2, Phase 31743
8
TestolactoneapprovedPhase 24968-93-413769
Synonyms:
(4AS,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-F]chromene-2,8(4bh)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
.DELTA.1-Dehydrotestolactone
.DELTA.1-Dehydrotestololactone
.DELTA.1-Testololactone
1 Dehydrotestolactone
1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone
1,2-Dehydrotestololactone
1,2-Didehydrotestololactone
1,2-didehydrotestololactone
1-Dehydrotestolactone
1-Dehydrotestololactone
1-dehydrotestololactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI)
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone
17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione
17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione
2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone
3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
968-93-4
AC1L22FS
Bristol Myers Squibb Brand of Testolactone
Bristol-Myers Squibb Brand of Testolactone
C02197
C19H24O3
CHEBI:9460
CHEMBL1571
CID13769
D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione
D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione
 
D00153
D013738
DB00894
Delta(1)-testololactone
Delta-1-testololactone
EINECS 213-534-6
Fludestrin
HSDB 3255
LMST02020084
LS-102968
MolPort-004-286-011
NCI60_001908
NSC 23759
NSC-12173
NSC23759
SQ 9538
SQ-9538
TESLAC (TN)
Teolit
Teslac
Teslak
Testolacton
Testolactona
Testolactona [INN-Spanish]
Testolactone
Testolactone (USP/INN)
Testolactone [USAN:INN]
Testolactonum
Testolactonum [INN-Latin]
Testolattone
Testolattone [DCIT]
Testolattone [Dcit]
UNII-6J9BLA949Q
ZINC04081771
delta(1)-Dehydrotestolactone
delta(1)-Testolactone
delta(1)-Testololactone
9
AlendronateapprovedPhase 2155121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
66376-36-1
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
Alendronate
Alendronate Sodium
 
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
Binosto
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
10
Anastrozoleapproved, investigationalPhase 2262120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
11
Fulvestrantapproved, investigationalPhase 2173129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
 
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
SID29215034
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
12Hormone AntagonistsPhase 2, Phase 110002
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 2, Phase 19988
14EstrogensPhase 2, Phase 12144
15Antineoplastic Agents, HormonalPhase 24256
16Aromatase InhibitorsPhase 2, Phase 1721
17Estrogen AntagonistsPhase 2, Phase 11155
18
Letrozoleapproved, investigationalPhase 1358112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
19
Histamine Phosphateapproved90651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
20Neurotransmitter Agents14795
21
histamine90675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1

Interventional clinical trials:

(show all 16)
idNameStatusNCT IDPhase
1A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
2Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of BoneRecruitingNCT00445575Phase 2, Phase 3
3Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001728Phase 2
4Testolactone for the Treatment of Girls With LHRH Resistant Precocious PubertyCompletedNCT00001181Phase 2
5Arimidex in McCune Albright SyndromeCompletedNCT00055302Phase 2
6TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONERecruitingNCT01791842Phase 2
7Faslodex in McCune Albright SyndromeActive, not recruitingNCT00278915Phase 2
8PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright SyndromeSuspendedNCT02743377Phase 1, Phase 2
9Effects of Letrozole on Precocious Puberty Due to McCune Albright SyndromeCompletedNCT00006174Phase 1
10Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright SyndromeCompletedNCT00001973
11Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001851
12The Influence of Bisphosphonates in the Oral Cavity in ChildrenCompletedNCT00402064
13Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeRecruitingNCT00001727
14Histamine Responsiveness in McCune-Albright SyndromeRecruitingNCT00318097
15Natural History of Cherubism Observational StudyRecruitingNCT01916772
16Genetic and Functional Analysis of CherubismRecruitingNCT01630447

Search NIH Clinical Center for Fibrous Dysplasia

Genetic Tests for Fibrous Dysplasia

About this section

Anatomical Context for Fibrous Dysplasia

About this section

MalaCards organs/tissues related to Fibrous Dysplasia:

33
Bone, Breast, Brain, Lung, Bone marrow, T cells, Liver

Animal Models for Fibrous Dysplasia or affiliated genes

About this section

Publications for Fibrous Dysplasia

About this section

Articles related to Fibrous Dysplasia:

(show top 50)    (show all 709)
idTitleAuthorsYear
1
Pre-delivery fibrinogen predicts adverse maternal or neonatal outcomes in patients with placental abruption. (27075198)
2016
2
Molecular Pathophysiology of Priapism: Emerging Targets. (25392014)
2014
3
Low molecular weight hyaluronan mediated CD44 dependent induction of IL-6 and chemokines in human dermal fibroblasts potentiates innate immune response. (25126764)
2014
4
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-Fluorouracil, irinotecan or oxaliplatin in colon cancer cells. (24172061)
2014
5
Increased levels of IL-6, IL-1I^, and TNF-I+ in Kashin-Beck disease and rats induced by T-2 toxin and selenium deficiency. (24037056)
2014
6
Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant SOD1 protein in squid axoplasm. (23509252)
2013
7
Novel diagnostic and prognostic biomarkers in biliary tract cancer. (23971898)
2013
8
Breast cancer survival in Ethiopia: A cohort study of 1,070 women. (24375396)
2013
9
Acanthamoeba T4 genotype associated with keratitis infections in Tunisia. (23052779)
2013
10
Herpes virus infection associated with interstitial nephritis in a beaked whale (Mesoplodon densirostris). (23237059)
2012
11
Atrioventricular node reentrant tachycardia in patients with congenitally corrected transposition of the great arteries and results of radiofrequency catheter ablation. (23159417)
2012
12
Langerhans cell histiocytosis preceding the development of juvenile xanthogranuloma: a case and review of recent developments. (21793710)
2011
13
Unusual presentation of congenital infantile fibrosarcoma in seven infants with molecular-genetic analysis. (21843073)
2011
14
NER and BER repair gene polymorphisms in a healthy north Indian cohort and comparison with different ethnic groups worldwide. (21338203)
2010
15
Hypertonicity-induced mitochondrial membrane permeability in renal medullary interstitial cells: protective role of osmolytes. (20511721)
2010
16
Images in clinical medicine. Giant congenital nevus. (19726769)
2009
17
Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. (18803625)
2008
18
MCM-2, Ki-67 and PCNA protein expressions in pT3G2 colorectal cancer indicated lymph node involvement. (18383884)
2008
19
Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. (18672609)
2008
20
Pathological features and gene mutation analysis in two pedigrees of diffuse palmoplantar keratoderma]. (17369150)
2007
21
The 'ngisipet' and trachoma prevention: solving the latrine problem in nomadic tribes. (18330442)
2007
22
In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. (17984937)
2007
23
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. (16319911)
2006
24
Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. (16700921)
2006
25
Genotype-phenotype correlation in recessive dystrophic epidermolysis bullosa: when missense doesn't make sense. (15816848)
2005
26
Nutrition-/diet-induced changes in gene expression in white adipose tissue. (16311219)
2005
27
Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. (14999773)
2004
28
Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients. (14678204)
2004
29
Co-expression of trkA and p75 neurotrophin receptor in extracranial olfactory neuroblastoma cells. (12175342)
2002
30
Molecular characterization of a Spanish isolate of Mycobacterium malmoense. (11881896)
2002
31
c-MYC: more than just a matter of life and death. (12360279)
2002
32
Guanylyl cyclases and signaling by cyclic GMP. (10977868)
2000
33
Functional results of operative treatment of rectal prolapse over an 11-year period: emphasis on transabdominal approach. (10344689)
1999
34
The prevalence of p53 immunoreactivity in anal canal carcinoma. (9769387)
1998
35
Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. (9590265)
1998
36
The neuronal death induced by endotoxic shock but not that induced by excitatory amino acids requires TNF-alpha. (9786205)
1998
37
Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. (9188445)
1997
38
Protein phosphatase 2A plays a critical role in interleukin-2-induced beta 2-integrin dependent homotypic adhesion in human CD4+ T cell lines. (9195132)
1997
39
Cell-growth regulation of the hamster dihydrofolate reductase gene promoter by transcription factor Sp1. (9363748)
1997
40
Early assessment of transplanted liver function: lignocaine clearance test (MEGX). (9253568)
1997
41
Characterization and cloning of p11, a transrepressor of Drosophila melanogaster retrotransposon 1731. (8559667)
1995
42
The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells. (7841039)
1995
43
Somatostatin selectively couples to G(o) alpha in HIT-T15 cells. (7813819)
1995
44
Protein kinase A phosphorylates cyclin D1 at three distinct sites within the cyclin box and at the C-terminus. (8058338)
1994
45
Etiology and pathogenesis of spontaneous venous thromboembolism]. (8273075)
1993
46
Retrospective review of 41 patients with endodermal sinus tumor of the ovary. (11578366)
1993
47
Treatment planning. Dysthymic disorder complicated by bouts of major depression. (3596481)
1987
48
Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. (3793549)
1986
49
The diagnosis of cerebral angioma. (13215185)
1954
50

Variations for Fibrous Dysplasia

About this section

Expression for genes affiliated with Fibrous Dysplasia

About this section
Search GEO for disease gene expression data for Fibrous Dysplasia.

Pathways for genes affiliated with Fibrous Dysplasia

About this section

GO Terms for genes affiliated with Fibrous Dysplasia

About this section

Cellular components related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1membrane-bounded vesicleGO:00319889.8BGLAP, SPARC

Biological processes related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1response to gravityGO:000962910.3BGLAP, SPARC
2bone developmentGO:006034810.2BGLAP, GNAS
3positive regulation of cAMP biosynthetic processGO:00308199.7CALCA, GNAS
4positive regulation of JAK-STAT cascadeGO:00464279.6GH1, PRL
5cellular response to growth factor stimulusGO:00713639.5BGLAP, IBSP, SPARC
6response to drugGO:00424939.0BGLAP, GNAS, SST

Sources for Fibrous Dysplasia

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet